March 10, 2017
Mylan to sell major depressive disorder tablets in US
Mylan has launched Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer’s Pristiq Tablets in U.S..
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Mylan
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
December 30, 2016
Mylan launches three different tablets in US in two days
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
December 16, 2016
Mylan Launches generic for EpiPen adrenaline injection, fights rising US drug prices
Mylan is launching its generic for EpiPen adrenaline injection at a wholesale acquisition cost (WAC) of $300 per epinephrine injection. As…
December 9, 2016
Allergan dissapointed with PTAB’s reaction as Mylan petitions for IPR of Restasis patents
Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that…
November 3, 2016
Strides, Mylan settle Regulatory and General Claims on Agila transaction, Strides gets $30M
Strides and Mylan have agree to settle Regulatory and General Claims on Agila transaction.
November 20, 2015
Mylan in patent lawsuit
Mylan’s subsidiaries were sued Warner Chilcott and Qualicaps in connection with the filing of an ANDA with the FDA for Mesalamine Delayed-release Capsules.
November 17, 2015
Mylan launches generic version of Axert in US. $1B share repurchase plan authorized
Mylan N.V. has launch Almotriptan Tablets USP, 6.25 mg and 12.5 mg, the generic version of Janssen Pharmaceutical’s AXERT in the U.S.…